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( ABSTRACT 
The effects of device characteristics on the release of nitroglycerin 
from a silicone disc were evaluated. A series of silicone discs 
containing nitroglycerin was prepared at varying levels of drug 
concentration, surface area, and firmness. A modification of the 
U.S.P. Dissolution Method I was used to evaluate the effects of these 
parameters on the in-vitro release of nitroglycerin from the discs. 
Reverse-phase HPLC was used for the quantitative analysis. The in-vitro 
dissolution method appeared reliable and reproducible in that there was 
good correlation (r=0.920) of dissolution profiles in both commercial 
transdermal products and test systems. The experimental data indicate 
that drug concentration and surface area have the greatest effect on the 
rate and extent of release of nitroglycerin over a 24 hour period. 
Firmness of the matrix appeared to have no significant effect on the 
rate or total amount of drug released from the systems. 
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OBJECTIVE 
The recent addition of controlled delivery systems to the 
transdermal route of drug administration was expected to provide a 
method of drug delivery which would minimize absorption variability and 
maintain more constant blood levels of drug. However, studies have 
shown that unpredictable release can occur (Hollenberg, 1984; Weber, 
1984; Reichek, 1984; Olivari, 1983; Jordan, 1985; Karim, 1983), and 
evidence suggests that changes in certain physical and chemical 
characteristics may be responsible. The effects of these factors on 
controlled drug release have been found to vary between systems. 
The purpose of this study was to examine the individual and 
interactive effects of various device characteristics on the release of 
nitroglycerin from silicone discs. Data obtained in this study will 
contribute to the expanding field of drug release from·transdermal 
delivery systems. 
2 
INTRODUCTION 
1. Principles of Percutaneous Absorption 
1.1 The Skin 
The skin is considered the largest organ in the human body and its 
high accessability make it an excellent target for drug administration. 
In order to exert a systemic effect following application of a 
transdermal device, a drug must pass through one or more cell barriers 
or membranes. It is therefore necessary to consider the composition of 
this system and the transport processes involved in the movement of drug 
molecules across the intact membrane. 
The skin includes the tissue that covers the body along with the 
mucous membranes and modified cutaneous structures. The average surface 
area of the skin of an adult male is about 20 square feet and may weigh 
9 or 10 pounds. Human skin is a stratified tissue composed of three 
basic layers: the epidermis, the dermis, and the underlying tissue. 
The structure of the skin is shown in Figure 1. The functions of the 
skin include sensation, protection, thermoregulation and secretion. The 
skin forms an elastic resistant covering which protects man from the 
environment and prevents the passage of harmful physical' chemical and 
microbiological agents. (Mullins, 1980). 
The epidermis is a relatively thin layer, only 0.1 to 0.2 mm in 
thickness. The epidermis itself is composed of four layers: the 
stratum corneum, stratum lucidum, stratum granulosum, and the stratum 
germinativum. The stratum corneum forms the outermost layer of the 
epidermis. It is well established in the literature that the stratum 
( 
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----STRATUM CORNEUM 
~-- STRATUM LUCIOUM 
Figure 1. Cross-section of the skin. (Handbook of 
Nonprescription Drugs, 5th ed., p. 300, American 
Pharmaceutical Assoc., Washington, D.C., 1977) 
en 
~ 
a: 
w 
0 
Cl. 
w 
C/) 
~ 
a: 
w 
0 
C/) 
~ 
a: 
w 
0 
0 
Cl. 
>-
I 
( 
4 
corneum is the principal barrier to the permeation of drugs through the 
intact skin (Shaw, 1983). It is composed of 40 percent protein, 40 
percent water, and the balance is lipids. This layer is 10-15 um thick, 
is comprised of dead, dry cells, and it exhibits regional differences in 
thickness over the body (Michaels, et al, 1975). The cells of the 
stratum corneum are stacked in overlapping "columns" and are more 
ordered in the areas of thinner epidermis. Aggregates of keratin inside 
the cells of the stratum corneum are cross-linked in a characteristic 
folded configuration (alpha keratin), rendering the fibers elastic. 
When stretched, the keratin chain is drawn into a more linear form (beta 
keratin). 
The outermost surface of the stratum corneum is covered in a film 
made up of emulsified lipids, which act as a seal to bind the cells 
together. The surface has an acid pH, ranging from 4 to 6.5, depending 
on the area of the body. The lipid layer between the cells can be 
considered a bilayer, in that both polar and nonpolar sections are 
found. The components of this layer have been shown to be directly 
responsible for retarding penetration of many molecules into the body 
(Michaels, et al, 1975). 
The protein component of the stratum corneum is hydrophilic in 
nature and can be hydrated to swell the skin using the hydroxyl and 
amino groups on the molecules. The protein can also be altered by heat 
or chemicals, such as surfactants, to result in the conversion from 
alpha to beta configuration. The end result is greatly enhanced 
permeability of the skin. 
The skin as a body organ is constantly undergoing changes. The 
degree of hydration, thickness, and composition will vary as a function 
( 
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of age, race, and environmental conditions. Epidennal cell growth 
begins in the basal layer of the stratum germinativum. Cells generated 
in the basal area move toward the skin surface, changing in shape as 
they move. This process of cell turnover requires up to two months 
(Cooper, 1985). 
In addition to passage through the stratum corneum cells, molecules 
may also be transported through the follicular orifices and sweat gland 
ducts which scatter the surface of the skin. These provide alternate 
pathways for absorption although their significance is questionable. 
The contribution of the sweat glands and hair follicles has been 
investigated by several workers. According to Scheuplein (1972), 
substances can be absorbed via the appendages by a diffusion process. 
He calculated that the route via the glands is important for a brief 
period immediately after applying the test substance. Since these 
appendages account for only 0.1 to 1.0 percent of the total skin surface 
area, the transepidennal route must be the principal route for most 
materials. (Idson, 1975). 
1.2 Percutaneous Absorption 
Due to the nature of the stratum corneum, the process of 
percutaneous absorption is a passive one rather than an active one. 
"The absence of metabolic processes in the 'dead' keratinizing layers 
precludes any role for active transport" (Malkinson, 1977). This 
process occurs in two steps. Diffusion through the barrier layer is 
the first phase, and is affected only by physical factors as detennined 
by ambient conditions. The second phase is the clearance from the 
dennis and this depends on blood flow and other factors inherent in the 
6 
dennal constituents (Idson, 1975). There is a delay period after the 
drug is placed on the surface of the skin, during which the membrane 
becomes charged with the penetrant, and then a longer second period 
during which the chemical penetrates the skin and is removed to the 
circulation. It is this second period that is governed by Fick's laws 
of diffusion (Michaels, 1975; Barry, et al, 1985). According to Fick's 
first law, the drug must dissolve in its vehicle and diffuse to the skin 
surface. Then, according to the principles of diffusion, the drug is 
transported across the skin. Fick's law states, 
dQ= DA dc/dx dt , 
where the amount, dQ, of a substance diffusing in time, dt, across an 
area, A, is directly proportional to the change in concentration, de, 
over the distance traveled, dx. 11 011 is the diffusion coefficient and 
dc/dx is the concentration gradient. 
It has been shown that removal of the stratum corneum by successive 
11 stripping 11 with cellophane tape can significantly increase the skin's 
permeability. (Grasso, 1972). This process increases transepidennal 
water loss and can result in a 60-fold increase in penneability (Chi~n, 
1984). 
Properties inherent in the dosage fonn may also affect the rate of 
diffusion of a substance through the skin. Both the chemical and 
physical properties of the test material must be considered. Ideally, 
the drug should be potent (i.e., be effective in low concentrations) and 
should have a good hydrophilic/ lipophilic balance (generally 1 or 
greater) (Chien, 1982). Substances will be more rapidly released from 
( 
7 
vehicles having a low affinity for the penetrant. Pertinent factors 
here are related to the solubility of the penetrant in the vehicle, the 
rate of diffusion of the penetrant in the vehicle, and the rate of 
release of the penetrant from its base (Malkinson, 1977). The pH, 
melting point, and molecular weight of a compound all contribute to the 
degree of solubility of a drug in the skin (Shaw, 1983; Kligman 1984; 
Grasso, 1972). In the formulation of a vehicle for a topical drug 
application, many factors must be considered. Drug stability, specific 
product use, site of application and product type must be combined in a 
dosage form which readily releases the drug when it comes in contact 
with the skin. For a given concentration of a drug in a certain 
vehicle, the thermodynamic activity coefficient of the drug in the 
vehicle may vary from one vehicle to the next (Higuchi, 1960; Cooper, 
1984; Horhota, 1979). Penetration is greatest when the drug is present 
at its maximal solubility concentration. 
1.3 Factors affecting percutaneous absorption 
The permeation of molecules through the skin may be influenced by 
physiological, physicochemical and thermodynamic factors. Physiologic 
factors include the age and condition of the skin and the degree of 
hydration. The condition of the skin, namely intactness, is one of the 
most important factors affecting penetration. If the stratum corneum is 
damaged, water loss is increased and permeability is enhanced. 
Increased hydration of the skin appears to "open'' the compact substance 
of the stratum corneum and result in increased permeation of many 
substances. Hydration of the skin can be enhanced by occlusive 
dressings, and may result in 4-5-fold increases in permeability (Idson, 
8 
1975). Physical properties of the vehicle can improve the degree of 
occlusion produced, leading to hydration of the stratum corneum. The 
most occlusive vehicles are greases, oils and collodion. 
Permeability of the skin appears to decrease with increasing age. 
This may be due in part to the greater percentage of water in the body 
of an infant as compared to the adult (Behl, 1984). In general, the 
skin of young children is sensitive to chemical irritation and harsh 
environmental conditions. As they mature, the cells develop resistance 
to many substances. 
The effect of the site of application was noted in a study by 
Michaels, et al (1975), where it was shown that the permeation of 
scopolamine was greatest in regions where the stratum corneum is the 
thinnest. The post-auricular area possesses the thinnest layer, whereas 
the plantar region has the thickest (Idson, 1975). 
Temperature of the skin has also been shown to affect percutaneous 
absorption. Under normal in-vivo conditions, substances penetrate the 
skin within a very narrow temperature range. For lipid soluble 
substances, increasing the skin temperature lowers the viscosity of the 
tissue lipids, thus reducing the activation energies for diffusion. The 
dual effects of temperature and humidity have also been shown to 
increase percutaneous absorption (Idson, 1975; Grasso, 1972). 
2.0 Penetration Enhancers 
A variety of substances are known to enhance the transport of drugs 
across the skin. Substances included in the formulation of cosmetics, 
soaps, and detergents may also produce profound local changes which can 
affect the permeability of the skin to other compounds. In order for 
9 
these penetration enhancers to be effective, they must modify the 
stratum corneum in some way. Surfactants increase penetration due to 
their ability to denature protein (keratin), thus "opening up 11 the skin 
structure and -increasing its permeability. Other agents improve skin 
wettability, decrease surface tension or increase solute diffusivity 
(Keith, 1983; Hwang, 1983; Chien, 1982). 
Few agents have been studied as intensively as dimethylsulfoxide 
(DMSO). In-vitro comparative studies showed DMSO to be superior to 
other solvents in both enhancing penetration and in favoring dermal 
retention of a drug (Grasso,1972). In-vivo, DMSO has been found to 
accelerate the penetration of many substances, such as corticosteroids, 
salicylic acid, dyes, and antibiotics (Sekura, 1972; Kligman, 1984; 
Idson,1975). For materials absorbed from the surface, a 50 percent 
concentration of DMSO can enhance the permeability of dermal connective 
tissue, apparently through a depolymerizing effect on hyaluronic acid 
(Malkinson, 1977). Despite the extensive studies, the exact mechanism 
of action is still not clear. Other possible mechanisms include partial 
extraction of lipids and protein configurational changes resulting from 
replacement of water by the vehicle. 
Despite its potential in this respect, DMSO can also be quite toxic, 
causing refractive lens opacities, erythema, edema, and itching, and is 
noted also for the unpleasant taste and odor associated with its 
breakdown products (Sekura, 1972). Other, less toxic, agents have also 
been used as accelerants of drug transport. Surface-active agents 
(surfactants), especially the anionic surfactants, appear to alter the 
permeability of the skin to water. Propylene glycol and polyethylene 
glycol 400 have been known to both increase and decrease permeation of 
( 
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substances. Concentrations of 50 percent or greater usually disturb the 
barrier and increase the loss of water from the skin (Idson, 1985). 
Calcium thioglycolate, a commercial depilating agent, was shown to 
improve the transdennal absorption of theophylline in rats, giving a 
40-fold increase in plasma concentration over that of the control 
(Kushida, 1984). 
Recently, another agent, AZONE (Nelson Research and Dev. 
Co.,Irvine, CA) was shown to enhance the absorption of triamcinolone 
acetonide, and was effective in a concentration of only 1 percent. This 
substance has been shown to be more effective than DMSO, and so has been 
receiving increasing attention in the past year (Chow, 1984; 
Vaidyanathan, 1985). Chemically, l-dodecylazacycloheptan-2-one, AZONE 
is a structural analogue of pyrrolidone and methyldecyl sulfoxide. The 
range of concentrations of AZONE necessary for enhanced penetration is 
from 0.1 to 5 percent, indicating different partition coefficients for 
different drugs (Idson, 1985). 
3.0 Transdennal Drug Delivery 
The concept of using topical products to elicit a systemic response 
is not a new one. As early as 1900, systemic effects were reported 
following cutaneous application of belladonna, mercury, pilocarpine and 
cod liver oil (Grasso, 1972). Toxic, and even fatal, effects have also 
been reported from substances applied topically. Well known compou nds 
such as salicylic acid, organophosphates, and carbon tetrachloride can 
all produce toxic results. However, the topical use of therapeutic 
agents has many advantages over traditional routes of drug 
administration. For example, the topical administration of 
( 
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nitroglycerin in ointment formulations can minimize both the problems of 
extensive liver metabolism and short duration of activity. 
Over the last several years, considerable interest has developed in 
the area of controlled release of drug substances through the skin. 
Controlled or sustained-release systems are being used or tested to 
deliver an enormous range of drugs, including drugs for the treatment of 
glaucoma, angina, motion sickness, narcotics addiction, and 
hypertension. "A well-designed controlled-release delivery system can 
significantly reduce the frequency of dosing and also maintain a more 
steady drug concentration in the blood and target tissue cells" 
(Chien,1982). Transdermal patches allow a drug to enter the body at an 
approximately uniform rate over an extended period of time. A 
controlled-release transdermal delivery system can also lower the total 
daily dosage of a drug, decrease the incidence and severity of side 
effects, and avoid the variable absorption characteristics of other 
routes of administration. 
After the development of Ciba-Geigy's scopolamine-releasing 
transdermal delivery system, which releases drug at a continuous rate 
for 72 hours to control motion sickness, three nitroglycerin transdermal 
systems were developed independently by three pharmaceutical companies 
for once-daily medication of angina pectoris. 
The first was Transderm-NitroR, developed by Alza and marketed by 
Ciba-Geigy. It consists of an outer protective layer of aluminized 
plastic, a drug reservoir containing a nitroglycerin suspension, 
enclosed in a microporous ethylene- vinyl acetate copolymer diffusion 
membrane, and a hypoallergenic adhesive layer. The Key Pharmaceuticals 
product, Nitro-OurR, is a matrix diffusion-controlled delivery system in 
l 
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which nitroglycerin/ lactose triturate is homogeneously dispersed in a 
hydrophilic gel matrix. Finally, Searle's NitrodiscR consists of a 
solid, silicone-based polj1Tler and is called a "microsealed" delivery 
system, since nitroglycerin is uniformly dispersed throughout the 
matrix and diffuses out at a controlled rate (Chien, 1984; Black, 1982). 
Before transdermal patches, nitroglycerin was available in the form 
of sublingual tablets, sustained- release capsules, and ointments. The 
sublingual tablets allow rapid entry of the drug into the bloodstream 
but remain effective for less than 30 minutes. The time-released 
capsules are claimed to work for 8 to 12 hours. The ointments are 
applied to the skin once or twice a day, and are messy to use. It is 
difficult to get a uniform application each time a patient uses it. For 
all three marketed transdermal products, the devices contain sufficient 
nitroglycerin to maintain delivery of drug for 24 hours. The rate of 
delivery to the systemic circulation is determined by several factors, 
including the surface area covered and the characteristics of the skin 
itself (Fara, 1983). These transdermal systems permit minimal 
absorption variability while maintaining a constant drug level in the 
blood (Karim, 1983). 
Chien, et al (1983) performed skin permeation studies on the 
abdominal skin of the hairless mouse in order to examine and compare the 
controlled skin permeation kinetics of nitroglycerin delivered by these 
three transdermal delivery systems. Results indicated that the release 
rate profiles adhere fairly well to zero-order kinetics, although 
different release rates were found between the three systems. The total 
dose of nitroglycerin delivered at 24 hours by each system was close in 
magnitude although different technologies were used to manufacture them. 
13 
Other companies are also working on transdermal nitroglycerin 
systems (Sanders, 1985). Hereon division of Health-Chem Corp. is 
awaiting FDA approval for its NitrodermR system. This system consists 
of polyvinyl chloride copolymers and terpolymers and has a release-
control ling membrane. LecTec Corp. of Minnesota is working on a 
semisolid, hydrophilic gel system containing a polymeric adhesive to 
improve its strength and tackiness. Nelson Research and Development Co. 
of Irvine, California is working on its TranZoneR transdermal patches, 
which consist of a drug dispersed in various commercially available 
polymeric matrices along with the company's penetration enhancer, AZONE. 
Boehringer Ingelheim recently introduced its Catapres-TTSR (transdermal 
therapeutic system), which contains the antihypertensive clonidine. 
This patch effectively delivers drug for a period of seven days (Weber, 
et al , 1984) • 
4.0 Nitroglycerin 
Nitroglycerin has been used for over a century in the treatment of 
angina pectoris. Millions of patients throughout the world have placed 
nitroglycerin tablets under the tongue and have experienced rapid relief 
from the pain of angina. 
Nitroglycerin was first synthesized in 1846 by A. Sobrero, by mixing 
cold concentrated sulfuric and nitric acids with glycerin. The first 
reported use in medicine was in 1847 by Hering and Davis in Philadelphia 
(Krantz, 1975). 
( 
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Chemically, nitroglycerin is glyceryl trinitrate, or 
trinitroglycerin, 
CH 2-0-N02 
CH-O-N02 
CH2-0-N02 
The organic nitrates are dilators of arterial and venous smooth muscle. 
They reduce the requirement of the myocardium for oxygen by their 
effects on the systemic circulation. The sublingual route of 
administration of nitroglycerin is the most appropriate to relieve acute 
angina attacks and for immediate prophylaxis. The sustained- release 
formulations of nitroglycerin, namely the ointment, capsule, and 
transdermal formulations have prolonged pharmacologic activity. It has 
been postulated that the oral forms of nitroglycerin are ineffective 
because of their high hepatic degradation rates. However, studies have 
shown the oral forms to have prolonged pharmacologic activity (Needleman 
& Johnson, 1980). 
Organic nitrates, like other esters, undergo hydrolysis. This 
reaction occurs more rapidly in alkaline than acid conditions 
(McNiff,1980). The incubation of nitroglycerin in 4N sodium hydroxfde 
for fifteen minutes at 37 degrees Centigrade produced almost complete 
denitration, whereas treatment in 4N hydrochloric acid for six hours 
produced only a 28 percent decrease (Johnson, 1975). 
Pure nitroglycerin is highly explosive and is used in the 
manufacture of dynamite. Nitroglycerin for use in experimentation can 
be safely handled when adsorbed onto a suitable diluent such as lactose 
( 
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(Johnson, 1975). Nitroglycerin is heat labile and volatile {McNiff, 
1980). It is soluble in water to the degree of 1.2 to 1.8 grams per 
liter. Cacace {1979) found nitroglycerin to be stable in aqueous 
solution for six months under refrigeration. Incubation at 37 degrees 
Centigrade for six hours in water produced no detectable denitration 
(Johnson, 1975). 
Identification of nitroglycerin and its breakdown products {Figure 
2) has been done by spectrophotometric {McNiff, 1980), colorimetric 
(Bell, 1964), and chromatographic techniques. Spectrophotometric 
methods are time- consuming and complex and do not indicate stability, 
or differentiate nitroglycerin from its degradation products (Baaske, et 
al, 1979). Gas chromatography (GLC), although it requires a time-
consuming extraction step, has been used for its sensitivity. 
Quantitative data are possible even though nitroglycerin is thermally 
unstable {Wu, 1981). 
Several HPLC methods have been reported for the analysis of 
nitroglycerin and its in-vitro degradation products {Crouthamel & 
Dorsch, 1979; Baaske, et al, 1979; Wu, 1981; Baaske, et al, 1983; 
Gelber, 1980; Olsen & Scroggins, 1984). The HPLC methods are faster 
than GLC, and can be stability- indicating as well (Baaske, et al, 
1979). 
5.0 Methods for in-vitro release studies 
Many studies have been published, which carry out permeability 
measurements on cadaver skin and animal skin (Keith, 1983). The most 
widely reported in-vitro method for evaluating percutaneous absorption 
of drugs uses a membrane mounted between two fluid- filled chambers 
( 
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Figure 2. Breakdown of trinitroglycerin 
/ 
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(Akhter & Barry, 1985). The device, a diffusion cell, allows drug 
permeation to be monitored from the side exposed to the stratum corneum 
(donor) through to the dermal side (receptor) (Bronaugh, 1985). The 
Franz diffusion cell (figure 3) simulates clinical conditions by 
maintaining the receptor compartment at 37 degrees Centigrade while 
allowing the donor compartment to be exposed to ambient temperatures and 
humidities. The receptor compartment typically contains a propylene 
glycol or buffer solution to solubilize the drug and to simulate sink 
conditions. Hairless mouse skin or human cadaver epidermis may be used 
as the test membrane (Chien, 1983; Swarbrick, 1984; Behl, 1984; Cavey, 
1985). Silicone elastomers such as polydimethylsiloxane have also been 
used successfully as transport membranes (Hsieh, 1985; Flynn & Roseman, 
1971). In diffusion cell studies, permeation of drug across the 
membrane is affected by the composition of the donor solution. For 
example, the addition of fatty acids or alcohols to a solution of 
salicylic acid solution greatly increases the permeability of this drug 
across excised human abdominal epidermis. 
Another method for testing transdermal products is dissolution 
testing. Dissolution testing is the measurement of the rate and extent 
of dissolution of a drug substance in an immiscible liquid in an 
in-vitro test system. It is usually performed on oral dosage forms such 
as tablets and capsules as a quality control measure. All aspects of 
the test system and the sampling times are standardized by a compendial 
or regulatory agency. However, the physical characteristics of the drug 
substance, the dosage form, and other variables are controlled only by 
the manufacturer, and may differ significantly for one drug. The 
subject of in-vitro/ in-vivo correlation is quite complex. Due to these 
( 
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Figure 3 . Schematic illustration of Franz diffusion cell apparatus. 
( 
( 
19 
complexities, dissolution testing has been used only as a guide to the 
formulator in the early stages of drug product design, and 11 ••• as a 
quality control device to ensure process and batch-to- batch consistency 
for a particular formulation of a particular manufacturer" (Cooper, 
1984). At the present time, there are no official criteria for the 
regulation of dissolution testing of transdermal products, because of 
the wide range of products available. This method is used by a number 
of companies who manufacture transdermals for assessing the release 
characteristics of their devices. A distinct advantage of this method 
is that it eliminates the step of the transport of drug across a 
membrane (a difficult factor to control) and instead allows evaluation 
of the release characteristics of the device. 
( 
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EXPERIMENTAL 
1.0 MATERIALS AND SUPPLIES 
Citric acid (granular anhydrous), Pfizer Chemical Division, lot 
633100-H2041 
Ethanol 953 , USP 
Gel-silicone Q7-2218 Parts A and B, Dow Corning Corp., 
Midland, MI, lot HH05401 
1-Heptanesulfonic acid HPLC grade, Fisher Scientific, lot 732799 
Hydrogen peroxide 303, Fisher Scientific, lot 745518 
Methanol HPLC grade- Fisher Scientific, A-452 
Nitroglycerin 10%/lactose- Gyma Laboratories, Garden City, 
NY ,lot 09-9/82 
Propylene glycol, USP, J.T. Baker Chemical Co., lot 025395 
Scopolamine hydrobromide, USP, Amend Drug & Chemical 
Company, Irvington, NJ, lot G20293Kll 
Sodium hydroxide 0.1 N 
Tetrahydrofuran 
Transpore Tape (one-inch wide), 3M Corporation 
TridilR 5 mg/ml- American Critical Care ,lot 3CA180 
2.0 INSTRUMENTATION 
Blue-M oven 
Brookfield viscometer, model RVT (serial no. 51543) 
Flat-bottom kettles, 500 ml 
Linear chart recorder 
Metal shafts for rotating basket 
( 
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Micro-stir bars, 3 mm x 10 mm, Fisher Scientific Co. 
Reciprocal shaker 
Vankel Dissolution Apparatus 
Water-driven stirrers, GFS Chemical Company 
Waters Auto Sampler, WISP 710-B 
Waters C-18 u-Bondapak column (P/N 27324 S/N) 
Waters Associates Solvent Delivery System, model 6000A 
Waters Associates variable wavelenth detector, M-480 
( 
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METHODS 
1. Preparation of Silicone Discs containing Nitroglycerin 
Gel-silicone discs containing nitroglycerin were prepared by a 
polymerization method. The discs were made using gel-silicone Q?-2218 
Parts A and B (polydimethylsiloxane and a platinum catalyst) and 
nitroglycerin 10%/lactose triturate. Formulations were produced by 
varying one parameter for each batch in a 3x3x3 factorial design at 
three treatment levels for each parameter. The parameters evaluated 
were concentration, firmness and surface area. Final concentrations of 
10, 20 and 30 mg/cm3 were prepared. 
Variations in firmness were attained by changing the ratio of 
silicone to catalyst at three treatment levels, 1:1.5, 1:2.0, and 1:2.5. 
The silicone/catalyst mixture was preheated at 60 degrees Celsius for 15 
to 18 minutes to cause polymerization and produce a viscosity of 
approximately 1000 centipoise. The viscosity of the mixture was tested 
using the following procedure. Three formulations were prepared of the 
three ratios of polymer:catalyst. 50 ml of each were placed into 
plastic beakers and labeled for time and ratio. The samples were placed 
in a 60 degree Centigrade oven and removed at the appropriate time to be 
tested. A Brookfield viscometer was used with spindle sizes 3 and 4. 
The spindle was lowered into the sample to about 0.5 cm from the bottom 
of the beaker. It was rotated for one minute before the reading was 
taken. The average of three consecutive readings taken at every other 
rotation were taken and converted to centipoise values. 
( 
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After preheating the silicone/catalyst mixture for the appropriate 
length of time, the nitroglycerin/lactose was slowly stirred in 
manually. The polymer mixture was poured into a 10 11 x 711 stainless 
steel pan, covered with aluminum foil and set on a flat surface for 24 
hours to cure. Discs of three sizes were then cut from each of nine 
fonnulations, using aluminum cutters of 1.00, 1.25 and 1.50 inch 
diameters, for a total of twenty-seven batches. Each disc was weighed 
and the thickness was calculated based on surface area and weight. 
2. Degradation of Standard Nitroglycerin 
In order to observe the effects of degradation on nitroglycerin, the 
standard, TridilR , was subjected to acid, base, peroxide, heat, and a 
combination of heat and peroxide. Six test tubes were prepared 
containing 10.0 ml of a stock solution (40 mcg/ml). Tube number one 
was the control. To the second, third and fourth tubes, 10 drops of 1% 
citric acid, 0.1 N sodium hydroxide, or 30% hydrogen peroxide, 
respectively, were added. The fifth tube was placed in a 90 degree 
Centigrade oven for 60 minutes. The sixth tube contained 10 drops of 
30% hydrogen peroxide and was heated at 90 degrees Centigrade for 60 
minutes. After 60 minutes, each test tube was analyzed by HPLC under 
the aforementioned chromatographic conditions. 
3. Potency of 10% Nitroglycerin/lactose triturate 
The relative potency of the 10% nitroglycerin/lactose triturate was 
tested against TridilR 5.0 mg/ml injectable nitroglycerin. The United 
States Phannacopoeia requires that injectable drugs contain within (+) 
r 
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or (-) five percent of the labeled content. Due to this regulation, and 
the explosive nature of pure nitroglycerin, the use of an injectable 
nitroglycerin solution as a standard was deemed acceptable for our 
purposes. 
Four solutions (100, 135, 150, and 200 mcg/ml) were prepared using 
10% methanol in water to solubilize the nitroglycerin/lactose triturate. 
The solutions were vortexed for two minutes, left to stand for ten 
minutes, and then vortexed for one minute longer. HPLC was used to 
quantitate the samples. 
4. Dissolution 
Drug release studies were performed using conventional dissolution 
equipment. To assess in-vitro drug release from the vehicle, the 
dissolution apparatus (Figure 4) was set up following U.S.P. Dissolution 
Method I with some modifications. Flat-bottom kettles were substituted 
for round-bottom kettles. Stirring of the dissolution-media was 
provided by a magnetic stir-bar placed in the bottom of the kettle, 
driven by a magnetic stirrer located in the water bath beneath the 
kettle. Stirring was at approximately 80 rpm. A patch was attached to 
the bottom of a 250 ml Erlenmyer flask using Transpore Tape (3M Corp.). 
A hole in the tape slightly larger than the disc but smaller than the 
patch exposed the disc to the dissolution media. The mouth of the flask 
was fitted over the end of a rotating-basket shaft and lowered into the 
dissolution media, such that the bottom of the flask touched the media 
and was centered to the kettle. The dissolution media was 250 ml of 
distilled water. A gap of approximately 0.5 cm between the edge of the 
( 
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IN-VITRO DISSOLUTION APPARATUS 
A= WATER BATH 
B=SPINDLE DRIVE UNIT 
C=250 ml ERLENMEYER 
D=NITROGLYCERIN DISC 
E=SOO ml FLAT-BOTTOM KETTLE 
A I 
I 
L 
B 
E 
• F. 
. . 
F=DISSOLUTION MEDIA 
G=MICRO-STIR BAR 
H=WATER-DRIVEN STIRRER 
I=8-oz. JARS (SUPPORTS) 
J=THERMOMETER 
K=HEATING UNIT 
L= SHAFT 
K 
--
Figure 4. In-vitro dissolution apparatus. 
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Erlenmyer flask and the dissolution kettle was made through which 
samples were taken. 
Single samples (3 ml) were taken with replacement of media during a 
24-hour time period, according to the following time schedule: 0.5, 1, 
2, 4, 6, 8, 12, 18, and 24 hours. Samples were refrigerated until the 
time of analysis. 
5. Assay 
Reverse-phase high-performance liquid chromatography (HPLC) was used 
for the quantitative analysis of nitroglycerin release. The system 
consisted of a Waters Associates pump, model 6000A; Waters detector, 
model 480; Waters Intelligent Sampling Processor (W.I.S.P.), model 710B, 
for automatic and precise sample injection; and a Waters C-18 
u-Bondapack column. The chromatographic peaks were recorded using a 
Linear chart recorder (10 mV). 
Approximately one liter of mobile phase was prepared fresh daily by 
mixing 600 ml of methanol with 400 ml distilled water. The mobile phase 
was filtered through a 0.5 um filter prior to use. Chromatographic 
conditions included: the wavelength of 214 nm, the flow rate of 1.5 ml/ 
minute, the chart speed of 15 cm/hour, and an injection volume of 80 
mcl. The detector sensitivity was set at 0.5 (AUFS 0.5). A stock 
nitroglycerin solution was prepared for each time the assay was 
performed. The solution of 100 mcg/ml was prepared by diluting 1.00 ml 
of TridilR 5 mg/ml to 50.0 ml with distilled water in a 50 ml 
volumetric flask. The standard curve was produced by injecting 
increasing volumes of the stock solution, two injections each of 5, 20, 
40, 60, 80, and 100 mcl. This method of producing the standard curve 
( 
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was validated by comparison to the usual dilution method. Standard 
solutions of 5, 20, 40, 60, 80, and 100 mcl were prepared and 80 mcl of 
each solution was injected. Both methods were found to produce the same 
curve (r=0.985). 
6. Instron 
The relative firmness of the discs was quantitated using the Instron 
hardness tester, model 1122. Two discs from each batch of medium-sized 
(1.25 inch diameter) silicone discs containing nitroglycerin were 
tested. The samples were placed on weighing paper on the platform 
beneath the stainless steel probe. The crosshead and chart speeds were 
set at 50 and 100, respectively. Return limits were calculated for each 
sample in order to produce 50 percent deformation. At least four trials 
for each sample were performed, rotating the sample after each trial in 
order to test a new spot. The average values were calculated and 
converted to compression force in kilograms. 
7. Extractions 
In order to evaluate the total drug content per disc, an extraction 
procedure was done using two discs from each of the twenty-seven batches 
of silicone discs containing nitroglycerin. Using a metal spatula, the 
discs were cut into 5x5, 6x6, or 7x7 pieces, respectively for the 1.00 
inch, 1.25 inch, and 1.50 inch diameters. Each disc was placed in a 500 
ml volumetric flask with 200 ml of extracting fluid. The extracting 
fluid was composed of 80 percent ethanol and 20 percent tetrahydrofuran. 
Six flasks at a time were placed on a reciprocal shaker and shaken for 
( 
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two hours. A single sample was removed from each flask and filtered 
before assaying by HPLC. 
8. Penetration Enhancer Study 
A formulation was chosen from the twenty-seven batches of silicone 
discs containing nitroglycerin which showed relatively slow release 
characteristics. This formulation was composed of the high 
concentration of nitroglycerin (30 mg/ml), the 1.25 inch diameter, and 
the medium firmness (silicone to catalyst ratio of 1 to 2). Two batches 
of this formulation were prepared, one containing 10 percent and the 
other 20 percent dimethylsulfoxide (DMSO). The pol}11ler components were 
mixed and preheated, as before. The nitroglycerin/lactose triturate was 
stirred in, and finally the DMSO was added. Due to the small batch 
size, these formulations were injected into 1.25 inch molds rather than 
poured into sheets and cut. The volume injected was 2.5 ml, in order to 
maintain an average thickness of 0.3 cm. These were covered with 
aluminum foil and allowed to cure for 24 hours. 
9. Comparative studies 
The results of the nitroglycerin study were expected to indicate 
which parameters have the greatest impact on drug release from this 
system. The degree to which these effects can be applied to transdermal 
systems in general was tested by evaluating their contribution to the 
release of scopolamine from the same system. Scopolamine was chosen for 
this portion of the study since it is reported to possess percutaneous 
absorption properties (Chandrasekaran, et al, 1984), and since it is 
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already marketed as a transdennal drug delivery system (Transdenn-Scop, 
Ciba-Geigy). 
9.1 Preparation of Scopolamine Base 
Scopolamine free base was used rather than the hydrobromide salt 
since its physical characteristics (better lipid solubility) make it 
more suitable for transdennal delivery. The free base was prepared by 
dissolving 1.00 gram of scopolamine hydrobromide in 20 ml of methanol 
and 40 ml of chlorofonn. This was reacted with 20 ml of a 1 percent 
sodium bicarbonate solution (pH= 8.0) in a separatory funnel. This 
mixture was shaken and vented several times to complete the reaction. 
The methanol phase was separated off, leaving the scopolamine base 
dissolved in chlorofonn. The chlorofonn was allowed to evaporate by 
air, leaving the clear, viscous liquid scopolamine base. Several 
"batches" of the base were prepared and combined. The purity of the 
free base was verified by HPLC prior to use, using the hydrobromide salt 
as a reference. 
9.2 Preparation of Scopolamine discs and release studies 
Silicone discs containing scopolamine were prepared using two 
different concentrations of drug, 1% and 2%. The ratio of silicone to 
catalyst was 1 to 2, and the diameters chosen were 1.00 and 1.25 inches. 
The polymer/ catalyst mixture was preheated at 60 degrees Centigrade for 
12 to 15 minutes and the drug was carefully stirred in. The polymer/ 
drug mixture was poured into pans and allowed to cure for 24 hours 
( 
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before cutting the discs. The finished discs were weighed and the 
thickness was calculated. 
Release studies were perfonned using the same dissolution procedure 
as the nitroglycerin studies. Three discs each from the total of four 
batches were run. Samples were taken at 0.5, 1, 2, 4, 6, 8, 12, and 24 
hours and refrigerated until analysis. 
9.3 Scopolamine Assay 
The release of scopolamine was analyzed using the same HPLC system 
as in the nitroglycerin assay. The mobile phase consisted of 70 percent 
water and 30 percent acetonitrile with 10 ml of PIC (Paired Ionic 
Chromatography) reagent B-7 added per liter. This reagent was prepared 
by dissolving 11.0125 grams of !-heptane sulfonic acid in 50 ml 
distilled water in a 100 ml volumetric flask. To this was added 0.4 ml 
glacial acetic acid using an automatic pipette. The solution was 
brought to volume with distilled water and ten mls of PIC B-7 were added 
to a liter of mobile phase for a final concentration of 0.005 M. 
The chromatographic conditions included a flow rate of 1.5 ml per 
minute, detector sensitivity 0.02 AUFS, an injection volume of 30 ul, 
and the wavelength of 254 nm. 
( 
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RESULTS 
1. Manufacture of Discs 
Silicone discs containing nitroglycerin were manufactured using a 
polymerization process. The first step was to initiate the 
polymerization of the silicone gel. By varying the ratio of the 
silicone (Part A) to the catalyst (Part B}, a range of firmness levels 
was achieved. A:B ratios of 1:1.5, 1:2.0, and 1:2.5 were found to 
produce acceptable levels of firmness in the finished product. 
The silicone precursor used may be cured by a variety of 
temperatures and curing times. For our purposes, the mixture was 
preheated at 60 degrees Centigrade, until an appropriate viscosity was 
attained before adding the drug. Since nitroglycerin is a heat labile 
substance, the polymer was allowed to cool before the addition of the 
nitroglycerin to minimize loss of the active. Without this preheating 
step, and in the case where the polymer was insufficiently preheated, 
the nitroglycerin/lactose settled to the bottom of the beaker within a 
few minutes. The effect of various preheating times on the viscosity of 
the silicone mixture was investigated in order to determine an 
appropriate mixing schedule to produce uniform dispersion of the dr~g in 
the matrix. As seen in Tables 1 and 2, rapid increases in viscosity 
were seen after about 1000 centipoise. The time required for preheating 
the silicone varied slightly with the three levels of polymer:catalyst 
used, but an average of about 15 minutes was sufficient to exceed 1000 
centipoise. The polymer with the highest ratio of catalyst took the 
longest time to preheat. This was perhaps due to the large excess of 
liquid catalyst in the mixture, which would mask the gelling effect for 
32 
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Table 1. Preliiminary viscosity studies (time 0 to 18 minutes) 
Ratio A:B= 1:1.5 Ratio A:B= 1:2.0 Ratio A:B= 1.2.5 
time (min.) cps time (min.) cps time (min.) cps 
0 650 0 600 0 575 
I 
12 750 12 700 12 607 
14 1000 15 933 15 850 
16 2000 17 1400 18 1567 
18 3800 ) 21 (off) 20 (off) 
Table 2. Preliminary viscosity studies (takin g 16 minute sample 
and resuming viscosity testing) . 
Ratio A: B= 1: 1. 5 Ratio A:B= 1:2.0 Ratio A:B=l:2.5 
time (min) cps time (min.) cps time (min. ) cps 
17.5 2300 17 llOO 17 1000 
18 2450 19 1250 18 1100 
18.5 2600 20 1400 19 1300 
19 2800 21 1500 21 1750 
20 2950 23 1650 23 2000 
21 3100 25 1750 26 2500 
22 4350 28 2000 28 2950 
23 4850 30 2200 30 3600 
24 7500 31 3800 
26 9500+ 33 4750 
34 5100 
35 5900 
( 
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a short period. This effect can also be seen in mixtures prior to 
heating; the 1:2.5 ratio had the lowest initial viscosity. Additional 
heating past the 1000 centipoise level produced a system too viscous to 
allow unifonn ·dispersion of the nitroglycerin/ lactose triturate. 
After dispersion of the nitroglycerin adsorbed powder, the polymer 
mixture was poured into pans and allowed to cure in sheet fonn at room 
temperature for 24 hours. To ensure unifonn thickness of the polymer 
sheet while curing, it was extremely important that the surface on which 
the pans were set to cure be level. Individual discs were cut from the 
sheets and weighed. The mean weight per batch was calculated (Table 3), 
and overall average weights by size were detennined to be 1.5561 t 
0.1432 grams (1.00 inch diameter), 2.3771 ± 0.2525 grams (1.25 inch 
diameter), and 3.4086 ± 0.3875 grams (1.50 inch diameter). Differences 
in thickness of gel between the two ends of a pan appeared to be most 
responsible for the variation in individual weights of silicone discs. 
75 percent of t he discs that were used in the release studies varied in 
weight less than 5 percent. The remaining discs were within 10 percent 
of mean weights. 
The actual thickness of the finished discs was not physically 
measured, but was calculated for each disc based on the weight and known 
surface area of the disc. It was found that 10.0 ml of uncured silicone 
weighed 10.0 grams, therefore the conversion factor of 1.0 gram/cm3 was 
used in the volume and thickness calculations. Table 4 contains the 
values of surface area, volume, and theoretical drug load of the discs 
produced at the three diameters. The average thickness of the discs was 
0.30 cm, with a range of 0.25 cm to 0.35 cm for most of the 27 batches. 
.--... 
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Table 3. Overall Weight Variation of Nitroglycerin Discs (by batch) 
(*a=conc., b=firmness,c= S.A. ; l=low or small, · 2=me~L ~ 3= highest) 
Batch Description* Werft + S.D. Range (gm) in Range (cm) in Mean 
# a b c (gm n=l0-14 weight thickness thickness (cm) 
1 1 1 1 1. 5380+ 0. 1797 1. 2169-1. 7659 0.24-0.35 0.30 
2 1 1 2 2.2760+ 0.2704 1. 9088-2. 5648 0.24-0.32 0.30 
3 1 1 3 3.3742+ 0.5810 2.7031-4.2232 0.24-0.37 0.30 
4 2 1 1 1.5179+ 0.0782 1.4192-1. 7005 0.28-0.34 0.30 5 2 1 2 2.3845+ 0.1790 2.2062-2.7336 0.28-0.34 0.30 
6 2 1 3 3.3882+ 0.2882 3.0240-4.0887 0.27-0.36 0.30 
7 3 1 1 1. 5707+ 0.1350 1.2973-1. 7715 0.26-0.35 0.31 
8 3 1 2 2.3790+ 0.2051 2.0569-2.5782 0.25-0.36 0.30 w 9 3 1 3 3.4716+ 0.2775 3.1238-4.0441 0.26-0.36 0.31 ~ 
10 1 2 1 1.4464+ 0.1073 1. 3235-1. 6390 0.26-0.32 0.29 
11 1 2 2 2.4143+ 0.2431 2.0377-2.8732 0.25-0.36 0.30 
12 1 2 3 3.3250+ 0.4747 2. 6549-4. 1052 0.25-0.36 0.29 
13 2 2 1 1.6209+ 0.2196 1.2832-2.0664 0.28-0.36 0.32 
14 2 2 2 2.3562+ 0.3480 1.6212-2.9040 0.25-0.36 0.30 
15 2 2 3 3. 4482+ 0. 6710 2.2511-4.5368 0.26-0.36 0.30 
16 3 2 1 1. 6030+ 0.1578 1.3970-1.8858 0.28-0.37 0.31 
17 3 2 2 2.4031+ 0.3100 1. 8210-2. 8693 0.27-0.36 0.30 
18 3 2 3 3.4261+ 0.3289 2.8749-3.9024 0.25-0.34 0.30 
19 1 3 1 1. 5227+ 0 .1627 1. 2983-1. 8114 0.26-0.36 0.30 
20 1 3 2 2.2938+ 0.3323 1.9629-2.8348 0.26-0.36 0.29 
21 1 3 3 3.3976+ 0.3962 2. 8779-4. 0910 0.25-0.36 0.30 
22 2 3 1 1.5092+ 0.1511 1.3688-1.8626 0.27-0.37 0.30 
23 2 3 2 2.4761+ 0.2512 2.1170-2. 7444 0.27-0.35 0.31 
24 2 3 3 3.4188+ 0.3176 2.9519-3.8268 0.26-0.34 0.30 
25 3 3 1 1. 5966+ 0. 097 2 1. 4980-1. 8169 0.30-0.36 0.32 
26 3 3 2 2.3754+ 0.1331 2.2394-2.6425 0.28-0.33 0.30 
27 3 3 3 3.4258+ 0.1517 3.1895-3.6966 0.28-0.32 0.30 
Di sc diameter 
in. cm 
1. 00 2. 54 
1. 25 3 .18 
1.50 3.81 
* Table 4. Theoretical volume and tota l dru g content of silicone discs. 
Surf ace area 
cm
2 
5.07 
7.94 
11.40 
* 
Volu me 
3 
cm 
1. 52 
2.38 
3. 42 
Cone. 1 
(10 mg/cm3) 
15.20 
23.80 
34.20 
Based on average thic knes s of 0.30 cm 
Cone. 2 Cone. 3 
(20 mg/cm3) (30 mg/cm3) 
30.40 
47.60 
68.4 
45.60 
71.40 
102. 60 
,,.--... 
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The relative firmness of the discs was quantified using the Instron 
hardness tester. This instrument produced reliable values for 
comparison, using a standard procedure. The compression force in 
kilograms required to produce a 50 percent deformation of the discs was 
measured at several points on two discs from each medium size (1.25 inch 
diameter) batch (Table 5). Compression force as a function of firmness 
(Figure 5) and of concentration (Figure 6) were plotted. In general, as 
the total amount of catalyst was increased, the compression force also 
increased. Likewise, increasing the drug concentration produced an 
increase in the compression force, indicating a firmer disc (30 mg/cm3> 
20 mg/cm3 > 10 mg/cm3). In Figure 5 the discs having the highest 
concentrations of drug showed the highest compression rates and 
increased in a linear fashion as the catalyst ratio increased (r= 
0.997). The 10 and 20 mg/cm3 discs produced increased compressions 
relative to concentration and catalyst levels, however there appeared to 
be a leveling effect from the catalyst (r= 0.983 and 0.939 for the 20 
and 10 mg/cm3 concentrations). 
When compression force was plotted as a function of concentration, 
the results were similar in that higher ratios of catalyst and higher 
concentrations produced higher compressional forces. The slopes 
increased as a function of catalyst level and the linearity was better 
than generally seen in Figure 5 (R= 0.998, 0.978, 0.962). In any case, 
we can conclude that higher catalyst levels and concentrations of 
suspended material produce firmer discs. The significance of this 
finding was tested by evaluating the effect of firmness of release of 
drug from the discs. 
~ 
Table 5. Instron Studies: Compression force* as a measure of firmness. 
Firmness 
Concentration Low ( 1: 1. 5) Medi um (1 : 2 . 0) Firmest (1:2.5) 
--
10 mg/cm3 0.60 1. 05 1.15 
20 mg/cm3 0.88 1. 27 1. 47 
30 mg/cm3 1. 23 1. 75 2.41 
* force (kg) required to produce 50% deformation 
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• high cone. (30 mg/cm
3) 
2.5 • med. cone. (20 mg/cm
3) 
• low cone. 
(10 mg/cm3) 
2.0 
1. 5 
1.0 
0.5 
0 
1 Fl 
(1:1.5) 
Firmness ratio 
F2 
(1:2.0) 
F3 
(1:2.5) 
Figure s . Instron studies: compression force as a function 
of firmness ratio. 
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• high finnness level (1:2.5) 
• med. firmness level (1:2.0) 
• low firmness 1 evel (1:1.5) 
10 20 
Concentration (mg/crn3) 
Figure 6. Instron studies: Compression force as 
a function of drug concentration. 
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2. Analytical Methods 
In order to ensure a stability-indicating assay, it was necessary to 
observe the effect of nitroglycerin degradation on the absorption peak. 
A standard nitroglycerin chromatogram is shown in Figure 7. The 
retention time of the standard nitroglycerin was 3.90 minutes. A 
base-degraded sample produced the greatest change in the absorption 
peak, with the appearance of two additional peaks at 1.84 and 2.70 
minutes (Figure 8). 
Preliminary stability studies on the nitroglycerin standard 
solutions suggested that aqueous solutions of TridilR were stable under 
refrigeration for at least two weeks with no significant loss of 
potency. Further investigation supported this finding, although fresh 
standards were made daily. 
Daily tests of precision of the analytical methods showed a relative 
standard deviation of less than one percent (0.52 ± 0.53 percent) over a 
four month period. Daily standard curves consistently (r= 0.999) 
produced average slopes of 2.2992 ± 0.221, for a relative standard 
deviation of 9.6 percent over a three month period. 
Potency testing of the nitroglycerin/lactose triturate against the 
TridilR injectable solution indicated 99.0 to 100.0 percent potency ?f 
the powder before manufacture of the discs. 
In order to initially assess the in-vitro release method, three 
commercial transdermal products were tested. The products were Key 
Pharmaceutical 's NitroDurR 10 cm2, Searle's NitrodiscR and Ciba's 
Transderm-NitroR-5. Each of these systems is designed to release 5 mg 
of nitroglycerin through the skin over 24 hours. Fluxes and rates of 
release for the first two hours and the final 12 hours (Table 6) were 
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Figure 7. Standard nitroglycerin chromatogram. 
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Figure 8. Base-degraded nitrogtycerin chromatogram. 
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Table 6. In-vitro Comparison Study of Trade Products 
Sample Load SA f 1 (0-2 hr) f2 (12-24 hr) Ratio mg rel. % rel. (n=3) (mg) (cm2) {mg/cm2/hr) (mg/cm2/hr) fl : f2 per 24 hr 
.+::> 
Nitro-Dur R 
w 
51 10 1. 07 0.14 76.43 43.50 85 
(Key ) 
N. d. R itro isc 16 8 0. 28 0.003 93.33 10.9 68 
(Searle) 
Transderm-Nitro 25 10 0.11 0.065 1. 69 18.50 74 
(Ciba-Geigy) 
( 
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calculated. Overall, it was found that the rate of nitroglycerin 
release from the commercial products was higher during the first two 
hours than in the last 12 hours, with the exception of the 
Transderm-NitroR rate which changed dramatically during the last 12 
hours (Figure 9). The Searle and Key products showed essentially no 
change in rate during the last 12 hours. Initial flux rates for the 
Key, Searle, and Ciba products were 1.07, 0.28, and 0.11 mg/cm2/hr, 
respectively, and 0.014, 0.003, and 0.065 mg/cm2/hr in the final 12 
hours. 
Total milligrams and percent of nitroglycerin released over 24 hours 
varied according to the formulation. NitroDurR and NitrodiscR 
demonstrated decreasing rates with time due to their relatively firmer 
systems which retarded the migration of nitroglycerin inside the disc to 
the surface. 
3. Disc Extractions 
The results of the disc extraction study are shown in Table 7. An 
overall mean of 60 percent extraction was found. The effects of size 
and concentration on the total percent of drug extracted from the discs 
appeared to be insignificant. 
The fact that only 60 percent of the theoretical drug load was 
extracted leads to several possible conclusions which include incomplete 
extractions, drug decomposition, standard decomposition, and physical/ 
chemical interaction of the drug within the silicone. 
The first three possibilities were examined during the method and 
assay validation processes. In developing the extraction process, a 
second extraction of each disc using fresh fluid was attempted, but no 
50 
40 
30 t 
0 ~ 
w 
V'l 
< 
w 
_.. 
w 2() 
a: 
<!I 
:E 
10 
-
B ~ ~ ~ ~ ~ I f B Q £ l ~ I ~ Q £ l ~ ~ Q I f ~ Q Q ~ ~ ! ~ 
/- • NITRO-DUR (KEY) 
• NITRODISC (SEARLE) 
• TRANSDERM-NITRO (CIBA) / 
l 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
TIME (HOURS) 
Figure 9. Release profiles of trade products: Nitro-Dur (Key), Nitrodisc (Searle), 
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Table 7. Release and Extraction Data from Nitroglycerin Discs 
(*a=conc., b=firmness, c=SA; l= low, 2=med,3=highest) 
Batch Descrip.* Amount rel . % rel. mg extr. % extr. 
# a b c (mg) n=3 per 24 hr 
'· 1 l l l 10.28 68.55 9.98 65.80 
2 1 1 2 14.99 62.91 15.41 60.23 
3 1 1 3 23.59 64.45 22.78 64.62 
4 2 1 1 14.82 49.66 19.13 62.74 
5 2 1 2 27.27 74.17 29.21 56.54 
6 2 1 3 34.31 51.06 m m 
7 3 1 1 18.08 40 . 19 26 . 03 56.95 
8 3 1 2 19.95 28.25 m m 
9 3 1 3 30.03 28.40 m m 
10 1 2 1 !9. 99 64.23 8.51 34.14 
11 1 2 2 17.56 71. 67 14.48 58.11 
12 1 2 3 24 . 23 66.16 19 . 60 57.68 
( 
13 2 2 1 14.30 30.24 16.49 54.39 
14 2 2 2 23.28 45.93 27.04 58. 72 
15 2 2 3 30.33 51.13 33.86 53.81 
16 3 2 1 15.44 33.90 28.28 58.30 
17 3 2 2 27.36 35.99 43.74 58.73 
18 3 2 3 35.96 35 .89 55.37 51.47 
19 1. 3 1 9.54 63.45 7.12 54.07 
20 1 3 2 14.30 61.61 16.55 59.74 
21 1 3 3 21. 93 70.39 18.28 58.45 
22 2 3 1 13.00 44.90 18.44 61.36 
23 2 3 2 27.75 45.87 25 . 19 57.90 
24 2 3 3 31.04 45.80 43.43 56.92 
25 3 3 1 16.15 35.47 29 . 59 61. 92 
26 3 3 2 21.27 30.18 41. 54 61.83 
27 3 3 3 35.32 34.39 53.49 55.90 
m= missing data 
( 
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additional drug could be extracted. The initial potency testing of the 
nitroglycerin/ lactose triturate indicated at least 99.0 percent potency 
of the powder against the standard. Later assays did not indicate any 
significant loss of potency of the powder. Also, subsequent release 
studies, using a completely randomized design, showed no effect of 
storage time on the total percent of drug release. 
Finally, the possibility of decomposition of the standard was also 
excluded, since fresh standard solutions were made daily. Once an 
ampule of the standard TridilR injectable had been opened, it was stored 
under refrigeration in a tightly sealed glass test tube, and was not 
used for more than seven days. After seven days, stability tests were 
performed on the standard, and indicated no loss in potency for 2-3 
additional weeks. 
An interesting point to be made here relates the total percent of 
drug extracted for each batch of discs to the 24-hour release data for 
those batches. In subsequent drug release studies, the greatest percent 
of nitroglycerin release over 24 hours (based on theoretical drug load) 
that could be achieved was only about 70 percent. A comparison of the 
percent extracted per batch to the percent released per batch indicated 
that there may be a limit to the potential drug release from a disc of 
this type. There always appeared to be some drug remaining in the disc 
that is a function of the driving force of the drug in the silicone. If 
only 60 percent of drug in any given batch could be extracted, then 
perhaps the active drug release was closer to 100 percent. 
( 
( 
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4. Release Studies 
Subsequent drug release studies indicated that the pattern of 
in-vitro release of nitroglycerin from the transdermal discs very 
closely mimicked that of Searle's NitrodiscR. For this reason, three 
additional samples of NitrodiscR were run at random on separate dates 
among the experimental discs. This was done to test the reliability of 
the drug release apparatus. As seen in Figure 10, no significant 
differences were noted in the rate or extent of nitroglycerin release 
from three NitrodiscR samples. This finding is an indication of the 
reliability and reproducibility of this in-vitro dissolution method. 
Dissolution profiles of nitroglycerin release over 24 hours from 27 
batches of silicone discs are shown in Figures 11 through 19. In 
general, there was no leveling off of the curves. It appears that a 36 
or 48 hour profile might have produced a more accurate picture of drug 
release from these systems. Many of the batches could possibly release 
drug over a period of time greater than 24 hours. 
Samples of silicone discs containing nitroglycerin were tested at 
random, but were selected according to their weight. It was important 
to reduce the interfering effect of disc thickness for these studies, 
therefore discs were chosen which were within 5 percent of variation in 
thickness. However, due to the small batch size, it was occasionally 
necessary to select a disc which varied up to 10 percent from the mean. 
Approximately 75 percent of the samples were in the 5 percent range, and 
the remaining 25 percent of samples were in the 10 percent range. 
The percent-release data for each batch were plotted as a function 
of the square-root of time. The amount of drug released should be 
proportional to the square-root of time (Banaker, 1984; Pirotte & 
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Figure 10. Release profile of Nitrodisc (Searle) run on 3 separate dates. 
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Jaminet, 1984), and indeed this was the case. An overall linear 
correlation of 0.989 ± 0.013 was observed. Table 8 summarizes drug 
release as a function of the square-root of time. It is obvious from 
this table that drug concentration seemed to affect the slope of each 
plot. Concentration and slope were found to be inversely proportional, 
that is, an increase in drug concentration was associated with a 
decrease in the slope of the line. Percent release over 24 hours was 
directly proportional to the slope of the line. 
Close observation of table 8 reveals that, in most cases, the total 
percent release of nitroglycerin over 24 hours decreased with increases 
in concentration. This appears to be due to a function of the driving 
force of diffusion and the total drug load. As the total drug load was 
increased, a smaller percentage of drug was actually released since some 
drug must remain inside the matrix as the driving force. Table 8 also 
demonstrates the insignificance of the effect of firmness on drug 
release from these systems. For a given size and drug concentration, a 
change in firmness did not result in a significant 
drug release. 
(P< 0.01) change in 
Flux calculations were made from two portions of each dissolution 
profile. These two portions were those represented by the release of 
drug during the first 2 hours (f1) and the final 12 hours (f2). The · 
values of these two fluxes appear in Table 9. It is difficult to 
determine the extent of the interacting effects of concentration and 
surface area on the flux of drug from these systems. Subsequent 
statistical analysis makes these points clearer. Overall, it appears 
that concentration had the greatest influence on flux. However, a 
( 
( 
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Table 8. Drug release as a function of the square-root of time. 
(See table 7 for explanation of batch numbers) 
Batch # Total% rel./24 hr. Correlation {r} Slo~e 
1 68.56 0.982 16.32 
2 62.91 0.996 14.43 
3 64.45 0.995 13.47 
4 49.66 0.997 11. 39 
5 74.17 0.987 17.09 
6 51.06 0.996 11.62 
7 40.19 0.996 9.38 
8 28.25 0.989 6.27 
9 28.4' 0.998 6.32 
10 64.23 0.994 13. 02 
11 71.67 0.988 15.64 
12 66.16 0. 997 15.12 
13 30.24 0.999 6. 77 
14 45.93 0.944 10. 71 
15 51.13 0.998 11.62 
16 33.90 0.997 7.59 
17 35.99 0.995 ·8 . 07 
18 35.89 0.997 8.29 
19 63.45 0.993 13. 72 
20 61.61 0.985 13.53 
21 70.39 0.983 13. 79 
22 44.90 0.995 10.47 
23 45.87 0.995 10.24 
24 45.80 0.998 9.97 
25 35.47 0.977 7.57 
26 30.18 0.981 6.49 
27 34.39 0.955 7.36 
61 
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Table 9. Flux1 and flux2 for release of NTG from silicone discs. 
Batch* ·' f 1 (0-2 hr) f 2 (12-24 hr) Ratio mg released # (mg/cm2/hr) (mg/cm2/hr) fl:f2 per 24 hr. 
1 0.146 0.071 2.07 : 1 10.28 
2 0.223 0.053 4.24 14.99 
3 0.213 0.063 3.39 23.59 
4 0.248 0.061 4.08 14.82 
5 0.256 0.130 1. 96 27.27 
6 0.246 0.097 2.53 34.31 
7 0.242 0.115 2.56 18.08 
8 0.162 0.084 1.83 19.95 
9 0.172 0.146 1. 55 30.03 
10 0.242 0.062 3.88 9.99 
11 0.162 0.080 2.03 17.56 
12 0.172 0.067 2.59 24.23 
13 0.307 0.079 3.89 14.30 
14 0.302 0.063 4.80 23.28 
15 0.333 0.069 4.80 30.33 
16 0.392 0.074 5.30 15.44 
17 0.302 0.101 3.00 27.36 
18 0.302 0.084 3.60 35.96 
19 0.178 0.059 3.01 9.54 
20 0.192 0.061 3.16 14.30 
21 0.188 0.056 3.42 21. 93 
22 0.248 0.066 3. 77 13.00 
23 0.250 0.083 2.98 27.75 
24 0.270 0.034 7.84 31.04 
25 0.243 0.135 1.81 16.15 
26 0.266 0.106 2.52 21.27 
27 0.172 0.156 1.10 35.32 
( 
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closer look at the two flux rates in comparison with the other batches 
suggests another possibility. 
In comparing batches having the same value of f 1, we see a common 
factor of surface area. For example, batches 9, 12 and 27 have a flux 
rate of 0.172 mg/cm2/hr, and have the same surface area of 11.94 cm 2. 
Similarly, batches 7, 10 and 25 have f 1
1 s of 0.242 mg/cm2/hr and have a 
common surface area of 5.07 cm2. Since no other common formulation 
factors were noted between these batches, it appears that the initial 
flux of nitroglycerin from these systems is most influenced by the 
surface area of the discs. 
On the other hand, f 2 appeared to be influenced the most by the 
concentration of drug in the disc. For example, if we examine batches 
3, 10, 19 and 20, which had f 21 s of 0.063, 0.062, 0.059 and 0.061 
mg/cm2/hr, respectively, we find a common factor of low drug 
concentration (10mg/cm3). 
The ratios of f 1 to f 2 are also listed in Table 9. As can be seen 
from the data, no generalizations can be made with regards to increases 
in any formulation parameters, suggesting a possible interactive effect 
of these parameters. 
Analysis of variance (Figure 20) of the release data showed surface 
area (P< 0.01) and concentration (P< 0.01) to be significant factors · in 
the total release of nitroglycerin from the silicone discs. The 
firmness of the discs had no significant effect on the release of drug 
from these systems. Table 10 further illustrates this lack of 
significance of the firmness of the disc on total drug release over a 24 
hour period. The only apparent exception to this conclusion was with 
two groups of discs- batches 1, 10 and 19, and batches 4, 13 and 22, 
--
...--
Figure 20 . ANOVA (Analysis of Variance)* for 24-hour drug release 
Source df 
Concentration 2 
Firmness 2 
Surface Area 2 
Cone. x S.Area 4 
Cone. x Firm. 4 
Firm x S.Area 4 
Cone x Firm. x SA 8 
SS 
(sums of squares) 
1058.29 
58.58 
2616.52 
204.70 
104.85 
86. 70 
92.83 
F 
(SS ;. df) 
21.00 
1.16 
51. 92 
2.03 
1.04 
0.86 
0.46 
PR< F 
*** 0.0001 
0.3214 
*** 0.0001 
,OJ 1049 
0.3963 
0.4946 
0. 8776 
*Using Statistical Analysis computer .System (SAS) 
*** Significant ( ( 0.05 is significant) 
.-... 
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Table 10. Effect of firmness on mg NTG released per 24 hours. 
Finnness Cone. Surface area Batch # mg rel ./24 hr. 
(mgLcm3} (cm2} 
1 10 : 5.07 1 10.28 
2 II II 10 9.99 
3 II II 19 I 9. 54 
1 II 7.94 2 14.99 
2 II II 11 15.56 
3 II II 20 14.30 
1 II 11.40 3 23.59 
2 It 
" 
12 24.23 
3 It It 21 21. 93 
( 1 20 5. 07 4 14. 82 
2 It It 13 14.30 
3 
" 
It 22 13.00 
1 
" 
7.94 5 27.27 
2 II II 14 23.28 
3 II II 23 27.75 
1 It 11.40 6 34 . 31 
2 It II 15 30.31 
3 
" 
II 24 31 . 04 
1 30 5.07 7 18.08 
2 II 
" 
16 15.44 
3 II II 25 16.15 
1 II 7.94 8 19.95 
2 II It 17 27.36 
3 II 
" 
26 21.27 
1 II 11.40 9 30.03 
2 II 
" 
18 35.9& 
3 II 
" 
27 35 :32 
( 
f 
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where a subtle decrease in total milligrams released was noted as the 
firmness increased. These two groups were both of the small surface 
area (5.07 cm2) and the low and medium (10 and 20 mg/cm3) 
concentrations. 
5. Comparative 
Scopolamine base could not be uniformly dispersed into this silicone 
system. The base appeared as droplets of various sizes which did not 
dissolve when broken with a glass stirring rod. For this reason, 
reproducible release characteristics could not be expected. This is 
evident in the results of the release studies which show virtually no 
release of scopolamine from any sample during the 24 hour time period. 
The scopolamine base is a sticky, viscous liquid and is difficult to 
handle. Accurate weighing and mixing are essential in an evaluation of 
this type, but can not be guaranteed. 
Vigorous mixing with a glass stirring rod reduced the droplet size, 
however this method of mixing introduced air bubbles, which are 
undesirable and could not be removed. The scopolamine base soon settled 
back to the bottom of the beaker. 
6. Penetration enhancer study 
The addition of dimethylsulfoxide (DMSO) to silicone/ nitroglycerin 
formulations was expected to improve the release of nitroglycerin from 
systems which showed relatively slow release characteristics. However, 
at the levels tested, this did not occur. In fact, the addition of DMSO 
to these formulations prevented the cross-linking of the pol}111er, and 
( 
( -
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the formulation remained in a semi-liquid state. The Dow-Corning 
literature for the product used in these studies lists several compounds 
which are incompatible with polydimethylsiloxane, but DMSO was not one 
of them. 
Due to the lack of resources in the area of penetration enhancers, 
this portion of the study was not pursued. Other researchers in the 
field of transdermal drug release have indicated that the application of 
a penetration enhancer directly to the surface of the device (attempting 
to directly affect the stratum corneum) is a more successful approach 
than the encorporation of the penetration enhancer into the matrix 
(Sanders, 1985). 
( 
1. 
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CONCLUSIONS 
The firmness (as measured by force to produce 50 percent deform-
ation) of silicone disc matrices containing nitroglycerin on lactose 
increased as the concentration increased. 
2. The firmness of the discs did not significantly affect the release 
of nitroglycerin in the range studied. 
3. Release from these systems was not zero-order. 
4. An in-vitro dissolution method was developed to study the release 
characteristics of drug from silicone discs. The method appeared 
reliable and reproducible in that there was good correlation 
(r=0.920) of dissolution profiles in both commercial transdermal 
products and test systems. 
5. Surface area had the most significant effect on flux and total 
release of nitroglycerin. This effect was observed in systems at 
all three firmness and concentration levels. Flux was most affected 
by surface area during the first 2 hours of release, and by 
concentration during the final 12 hours of release. 
6. Flux was directly related to concentration (drug load). As the drug 
concentration was increased, the flux also increased. 
7. In all cases, not all of the drug was released from the discs. At 
most, 60 percent of the nitroglycerin was extracted from the 
silicone, indicating the an interaction between the drug and the 
silicone matrix. 
( 
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FUTURE WORK 
This study provided insight into how the release of nitroglycerin is 
affected by the design of the disc. Several possibilities exist for 
further investigation in the following areas: 
1. In retrospect, a wider range of firmness levels could probably more 
clearly define the significance of this factor on drug release. 
2. To evaluate a system using a more potent drug, i.e., one which would 
require a smaller drug load in the device, such as timolol or 
clonidine. 
3. To investigate the possibility of encorporating a more compatible 
penetration enhancer into these systems. Compatible penetration 
enhancers are currently being studied by other investigators and 
will find an increased use in commercial transdennal products. 
4. To compare this in-vitro method of drug release study to one 
utilizing diffusion cells with either excised skin or silastic 
membranes. 
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